X-linked Agammaglobulinemia: Symptoms, Treatment & Infection Risk

X-linked agammaglobulinemia (XLA) is a congenital inability to generate mature antibody-producing B lymphocytes. Pathogenic variants in BTK interrupt signalling required for B-cell development beyond the pro-B stage, so peripheral blood and tissues contain vanishingly few B cells and essentially no immunoglobulin production of the child’s own. Maternal IgG crosses the placenta and masks the defect for the first months of life; thereafter, boys experience recurrent pyogenic infections of ears, sinuses, and lungs, together with enteric pathogens and—critically—heightened vulnerability to certain viruses that are usually limited by neutralising antibody.

Because the adaptive humoral arm is missing, clinical reasoning centres on early immunology referral, structured replacement immunoglobulin, meticulous infection surveillance, and anticipation of rare but devastating complications such as enteroviral central nervous system infection or progressive lung injury from repeated pneumonias.

XLA sits within the inborn errors of immunity family as a predominantly antibody deficiency. Immunology teams classify severity by B-cell enumeration, immunoglobulin levels, infection frequency, and molecular confirmation. The table below contrasts features commonly used when triaging suspected cases on the ward.

↔On narrow screens, swipe horizontally to read all columns.

Typical pattern

After maternal antibody decay, infants and toddlers develop recurrent otitis, sinusitis, and bronchopneumonia; some present first with empyema or sepsis. Chronic or relapsing diarrhoea may reflect Giardia or other enteric pathogens. Fever may be blunted in young infants but often pronounced with invasive disease.

Atypical or later cues

Adolescents or adults diagnosed late can manifest bronchiectasis from years of untreated infections, autoimmune cytopenias, or inflammatory arthritis—contexts where teams still need to verify immunoglobulin levels and B-cell counts before attributing symptoms solely to unrelated diagnoses.

XLA follows X-linked recessive inheritance: affected males carry a single pathogenic BTK allele; female carriers are generally asymptomatic immunologically. Roughly half of boys have a de novo variant without a family history. There are no modifiable lifestyle causes—the risk is genetic. Secondary hypogammaglobulinaemia from agents such as rituximab is a different mechanism and requires separate immunology assessment.

Clinical assessment

Document infection frequency, hospital days, antibiotic classes used, growth, and family history of early male deaths or unexplained immune problems. Examine for lymphoid hypoplasia and chronic lung signs.

Laboratory investigations

• Serum immunoglobulins (IgG, IgM, IgA) with IgG subclasses as directed.
• Lymphocyte subset flow cytometry quantifying CD19⁺ or CD20⁺ B cells.
• Molecular testing for BTK variants when flow supports XLA.
• When febrile, collect blood cultures before antibiotics if safe and within bundle timelines.

Imaging

Chest imaging is not diagnostic but may reveal bronchiectasis or lobar consolidation guiding physiotherapy and MDT planning.

1. Suspect in a male with recurrent encapsulated infections plus low immunoglobulins—same-day paediatric/adult immunology advice.
2. Confirm absent B cells plus BTK sequencing; avoid presumptive “immune boosting” supplements—use evidence-based replacement.
3. Stabilise acute infection with appropriate antibiotics; escalate if sepsis criteria met.
4. Initiate or optimise immunoglobulin replacement per weight, IgG trough targets, and product choice (IV vs SC).
5. Prevent harm by auditing vaccines: inactivated schedules where indicated; live vaccines generally contraindicated.
6. Monitor trough IgG, infection diaries, growth, spirometry/imaging if chronic lung disease—adjust interval after every breakthrough event.

• Common variable immunodeficiency (CVID)—later onset, some B cells present, heterogeneous aetiology.
• Transient hypogammaglobulinaemia of infancy—B cells preserved; time-limited.
• Protein-losing enteropathies or nephrotic syndrome—IgG low but B cells normal; look for albuminuria or gut loss.
• HIV infection—cellular and humoral defects possible; screen per guideline where risk factors exist (HIV/AIDS overview).
• Drug-induced hypogammaglobulinaemia—temporal link to anti-CD20 or other immunosuppressants.

First-line

Lifelong immunoglobulin replacement (IVIG or SCIG) is standard. Dosing aims to maintain protective IgG troughs and reduce serious bacterial infections; exact gram/kg and interval are immunology-led.

Adjunctive

Prompt antibiotic therapy for proven or highly suspected bacterial infections; prolonged courses sometimes needed for deep-seated infection. Some patients receive prophylactic antibiotics during high-risk periods—only per written protocol.

Special populations

Pregnancy in female carriers is uncommon for disease expression but relevant for genetic counselling of offspring. Adolescent transition requires education on self-administration of SCIG, consent, and independent emergency access.

• Reconcile IgG troughs every 3–6 months when stable; shorten to 6–12 weeks after dose/route changes or hospitalisation for sepsis.
• Spirometry and HRCT intervals for chronic lung disease typically 12 months unless symptoms accelerate—coordinate with respiratory teams.
• Annual review of vaccine records before school or travel season; double-check electronic orders for live vaccines.
• Pharmacy collaboration for batch traceability, pre-medications (antihistamine/acetaminophen per protocol), and infusion pump limits.

Chronic sinopulmonary disease, bronchiectasis, malabsorption, autoimmune cytopenias, and enteroviral encephalitis are among the high-impact complications. Growth faltering from recurrent infection or chronic diarrhoea should trigger dietetics and immunology review.

Replacement immunoglobulin is the primary preventive strategy. Household hand hygiene, up-to-date inactivated vaccines for contacts where policy allows, and rapid treatment of focal infections limit structural lung damage. Counsel families to avoid live oral poliovirus exposure in regions still using oral polio vaccine—follow national travel health guidance.

With consistent immunoglobulin replacement and specialist follow-up, many patients attend mainstream school and work. Prognosis worsens with delayed diagnosis, untreated bronchiectasis, or enteroviral CNS infection—early recognition and adherence to replacement therapy remain the strongest modifiable factors.

Shift work revolves around infusion safety, accurate pre-infusion checks (identity, product, rate, emergency drugs), and coaching families to recognise sepsis versus infusion reactions. Language barriers or health literacy issues can delay reporting of subtle neurology—use teach-back when explaining red-flag symptoms.

• Vital signs at baseline, q15–30 min during IVIG ramp per protocol, then post-infusion observation window.
• SpO₂ and auscultation if respiratory symptoms or rate change during infusion.
• Pain score and neurological checks when headache or neck stiffness reported.
• Strict two-nurse or barcode verification for blood-product–like administration pathways.

• Non-blanching rash with hypotension after immunoglobulin—possible anaphylaxis.
• Fever with meningeal signs or rapidly dropping Glasgow Coma Scale.
• Severe respiratory distress, silent chest in a child, or SpO₂ <92% on appropriate oxygen.
• Hypotension or lactate elevation meeting sepsis screen in any febrile XLA patient.

Objective cues include rising oxygen requirement, falling blood pressure, rising NEWS2/MEWS, falling platelets in sepsis, or new focal neurology. Escalate to senior clinician and critical care early—patients lack antibody-mediated opsonisation and can decompensate swiftly. If enterovirus is circulating locally, lower threshold for senior review of febrile headache.

Pre-treatment

Verify cannula patency, baseline observations, allergy status, and whether pre-medications were given on time.

During treatment

Run IVIG strictly per infusion policy; pause for moderate reactions and escalate for severe reactions; maintain urinary tract infection surveillance when chronic catheters exist (avoid unless essential).

Education and evaluation

Teach families to keep an infection diary, recognise dehydration (affects troughs), and know when to bypass primary care for same-day hospital review.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, matrix matching, and cloze drops on the topic of immunoglobulin replacement safety, live-vaccine contraindications, encapsulated sepsis, and neurological red flags—mirroring the Clinical Judgment Measurement Model emphasis on cues, prioritisation, and escalation.